Company Monitoring Page for Agenus

latest headlines for company on cafepharma

BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific
Fierce Biotech
Mon, 08/5/24 - 11:10 am
Tags:
Bristol Myers Squibb, Tigit, Agenus, bispecific antibodies
Agenus to lay off 25% of staff, trim pipeline in cancer drug push
BioPharma Dive
Wed, 08/23/23 - 05:43 pm
Tags:
Agenus, layoffs, cancer, botensilimab, balstilimab
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer
Yahoo/Businesswire
Tue, 04/18/23 - 10:10 am
Tags:
Agenus, immuno-oncology, fast track, FDA, botensilimab, balstilimab
Agenus investors wake up to inevitability
EP Vantage
Tue, 10/26/21 - 10:34 am
Tags:
Agenus, balstilimab, cancer
Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
Fierce Biotech
Fri, 10/22/21 - 11:26 am
Tags:
Agenus, cervical cancer, balstilimab, Merck
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Fierce Biotech
Sat, 08/28/21 - 09:06 pm
Tags:
Agenus, FDA, balstilimab, cervical cancer, clinical trials
Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset
Fierce Biotech
Tue, 05/18/21 - 11:09 am
Tags:
Bristol Myers Squibb, Agenus, AGEN1777, M&A
First patient dosed with AgenTus’ cell therapy designed to clear COVID-19 virus while reducing inflammation
Biopharma Reporter
Mon, 11/9/20 - 11:09 am
Tags:
Agenus, cell therapy, agenT-797, COVID-19, clinical trials
BIO Roundup: Agenus, FDA, Merck’s Frazier and Much More
BioSpace
Sun, 06/9/19 - 01:49 pm
Tags:
Agenus, Jamie Dimon, BIO 2019, RWE, FDA, immuno-oncology, Merck, Ken Frazier, UK
Gilead Ends Year With Two Major Deals That Could Total More Than $3.125 Billion
BioSpace
Thu, 12/20/18 - 12:12 pm
Tags:
Gilead Sciences, Agenus, Scholar Rock, immuno-oncology
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Fri, 09/21/18 - 09:55 am
Tags:
Agenus, Incyte, Merck, Xoma
The Most Likely Incyte Acquisition Deal for 2017?
Motley Fool
Sat, 12/24/16 - 12:11 pm
Tags:
M&A, Incyte, Gilead Sciences, Lilly, Novartis, Agenus
Pfizer's Latest Immunotherapy Deal Could Be Great News for This Tiny Company
Motley Fool
Tue, 09/27/16 - 09:53 am
Tags:
Pfizer, Agenus, OncoImmune
Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?
Motley Fool
Tue, 06/14/16 - 10:08 am
Tags:
Pfizer, M&A, Agenus, cancer immunotherapy
Big Firms Love This Little Biotech
Motley Fool
Mon, 01/4/16 - 09:23 am
Tags:
Agenus
3 Biotech Stocks Under $5 That Could Explode Higher in 2016
Motley Fool
Sun, 12/27/15 - 10:28 am
Tags:
Geron, Agenus, Exelixis
3 Low-Price Biotech Stocks That Could Pop or Drop in 2016
Motley Fool
Fri, 08/21/15 - 08:50 am
Tags:
Agenus, Array Biopharma, Idera Pharmaceuticals
Agenus bags cancer antibodies in $44M deal
Fierce Biotech
Mon, 07/20/15 - 01:41 pm
Tags:
Agenus, cancer antibodies, Diatheva
Incyte, Agenus partner on immuno-oncology targets in $410M deal
Fierce Biotech
Fri, 01/9/15 - 09:56 am
Tags:
Incyte, Agenus, immuno-oncology
Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
TheStreet.com
Tue, 12/2/14 - 07:31 pm
Tags:
MediciNova, Agenus, CytRx, CTI BioPharma, Sunesis

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.